IDH mutations are considered to be an early event in gliomagenesis and are one of the most critical genetic biomarkers for high-grade gliomas having prognostic implications (improved survival with IDH mutant than wild-type glioblastomas {31 months vs 15 months}) (15). The gene discussed is IDH1; the disease is central nervous system cancer.